RS65996B1 - Azabenzimidazol jedinjenja i farmaceutska sredstva - Google Patents

Azabenzimidazol jedinjenja i farmaceutska sredstva

Info

Publication number
RS65996B1
RS65996B1 RS20241035A RSP20241035A RS65996B1 RS 65996 B1 RS65996 B1 RS 65996B1 RS 20241035 A RS20241035 A RS 20241035A RS P20241035 A RSP20241035 A RS P20241035A RS 65996 B1 RS65996 B1 RS 65996B1
Authority
RS
Serbia
Prior art keywords
methyl
pyridin
trifluoromethyl
imidazo
amino
Prior art date
Application number
RS20241035A
Other languages
English (en)
Serbian (sr)
Inventor
Kouya OIKAWA
Sho Hirai
Kazuhiko Wakita
Akiko FUJIBAYASHI
Original Assignee
Nippon Shinyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Shinyaku Co Ltd filed Critical Nippon Shinyaku Co Ltd
Publication of RS65996B1 publication Critical patent/RS65996B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/396—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having three-membered rings, e.g. aziridine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
RS20241035A 2018-05-08 2019-05-07 Azabenzimidazol jedinjenja i farmaceutska sredstva RS65996B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018089867 2018-05-08
PCT/JP2019/018201 WO2019216294A1 (ja) 2018-05-08 2019-05-07 アザベンゾイミダゾール化合物及び医薬
EP19800286.7A EP3792260B1 (en) 2018-05-08 2019-05-07 Azabenzimidazole compounds and pharmaceutical

Publications (1)

Publication Number Publication Date
RS65996B1 true RS65996B1 (sr) 2024-10-31

Family

ID=68467433

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20241035A RS65996B1 (sr) 2018-05-08 2019-05-07 Azabenzimidazol jedinjenja i farmaceutska sredstva

Country Status (35)

Country Link
US (1) US12319683B2 (cg-RX-API-DMAC10.html)
EP (1) EP3792260B1 (cg-RX-API-DMAC10.html)
JP (1) JP7235047B2 (cg-RX-API-DMAC10.html)
KR (1) KR102819951B1 (cg-RX-API-DMAC10.html)
CN (1) CN112368282B (cg-RX-API-DMAC10.html)
AU (1) AU2019265134B2 (cg-RX-API-DMAC10.html)
BR (1) BR112020022662A2 (cg-RX-API-DMAC10.html)
CA (1) CA3099655A1 (cg-RX-API-DMAC10.html)
CL (1) CL2020002868A1 (cg-RX-API-DMAC10.html)
CO (1) CO2020013848A2 (cg-RX-API-DMAC10.html)
DK (1) DK3792260T3 (cg-RX-API-DMAC10.html)
EC (1) ECSP20078586A (cg-RX-API-DMAC10.html)
ES (1) ES2992256T3 (cg-RX-API-DMAC10.html)
FI (1) FI3792260T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20241414T1 (cg-RX-API-DMAC10.html)
HU (1) HUE068695T2 (cg-RX-API-DMAC10.html)
IL (1) IL278517B2 (cg-RX-API-DMAC10.html)
LT (1) LT3792260T (cg-RX-API-DMAC10.html)
MA (1) MA52587B1 (cg-RX-API-DMAC10.html)
MD (1) MD3792260T2 (cg-RX-API-DMAC10.html)
MX (1) MX2020011855A (cg-RX-API-DMAC10.html)
MY (1) MY202833A (cg-RX-API-DMAC10.html)
PE (1) PE20211384A1 (cg-RX-API-DMAC10.html)
PH (1) PH12020551873A1 (cg-RX-API-DMAC10.html)
PL (1) PL3792260T3 (cg-RX-API-DMAC10.html)
PT (1) PT3792260T (cg-RX-API-DMAC10.html)
RS (1) RS65996B1 (cg-RX-API-DMAC10.html)
SA (1) SA520420487B1 (cg-RX-API-DMAC10.html)
SG (1) SG11202011003TA (cg-RX-API-DMAC10.html)
SI (1) SI3792260T1 (cg-RX-API-DMAC10.html)
SM (1) SMT202400407T1 (cg-RX-API-DMAC10.html)
TW (1) TWI868068B (cg-RX-API-DMAC10.html)
UA (1) UA126774C2 (cg-RX-API-DMAC10.html)
WO (1) WO2019216294A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA202007164B (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY202833A (en) 2018-05-08 2024-05-24 Nippon Shinyaku Co Ltd Azabenzimidazole compounds and pharmaceutical
CA3160838A1 (en) * 2019-11-13 2021-05-20 Nippon Shinyaku Co., Ltd. Therapeutic agents and prophylactic agents for functional gastrointestinal disorders and xerostomia
CA3161582A1 (en) 2019-11-13 2021-05-20 Nippon Shinyaku Co., Ltd. Azabenzimidazole compound and medicine
CN118045050B (zh) * 2023-11-16 2025-06-10 中山大学肿瘤防治中心(中山大学附属肿瘤医院、中山大学肿瘤研究所) 一种头颈部放疗患者适用的缓解口腔干燥的组合物及其制备方法
CN122422310A (zh) * 2024-01-17 2026-07-17 盛睿泽华医药科技(苏州)有限公司 可溶性环氧水解酶抑制剂及其应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571819A (en) 1994-11-22 1996-11-05 Sabb; Annmarie L. Imidazopyridines as muscarinic agents
NO2005012I1 (no) 1994-12-28 2005-06-06 Debio Rech Pharma Sa Triptorelin og farmasoytisk akseptable salter derav
UA73543C2 (uk) 1999-12-07 2005-08-15 Тераванс, Інк. Похідні сечовини, фармацевтична композиція та застосування похідного при приготуванні лікарського засобу для лікування захворювання, яке опосередковується мускариновим рецептором
TW200538095A (en) 2004-03-11 2005-12-01 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
EP1723142A1 (en) 2004-03-11 2006-11-22 Theravance, Inc. Diphenylmethyl compounds useful as muscarinic receptor antagonists
EP1734820A4 (en) 2004-04-16 2008-01-23 Neurogen Corp Imidazopyrrazine, imidazopyridine, and imidazo-pyrimidine as CRF1 receptor ligands
EP2275096A3 (en) 2005-08-26 2011-07-13 Braincells, Inc. Neurogenesis via modulation of the muscarinic receptors
ES2274712B1 (es) 2005-10-06 2008-03-01 Laboratorios Almirall S.A. Nuevos derivados imidazopiridina.
EP2054405B1 (en) 2006-07-11 2013-09-18 Daewoong Pharmaceutical Co., Ltd. Novel biaryl benzoimidazole derivatives and pharmaceutical composition comprising the same
US8008307B2 (en) 2006-08-08 2011-08-30 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of E1 activating enzymes
GB0706168D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
EA201001205A1 (ru) 2008-01-24 2011-04-29 Юсб Фарма, С.А. Соединения, содержащие циклобутоксигруппу
US9085507B2 (en) 2009-05-11 2015-07-21 Ratiopharm Gmbh Desfesoterodine in the form of a tartaric acid salt
WO2011018894A1 (en) 2009-08-10 2011-02-17 Raqualia Pharma Inc. Pyrrolopyrimidine derivatives as potassium channel modulators
JP5667934B2 (ja) * 2010-06-28 2015-02-12 大日本住友製薬株式会社 新規2環性複素環化合物からなる医薬
TWI541243B (zh) 2010-09-10 2016-07-11 拜耳知識產權公司 經取代咪唑并嗒
US20140135319A1 (en) 2010-12-17 2014-05-15 Bayer Intellectual Property Gmbh 6-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
US20140187548A1 (en) 2010-12-17 2014-07-03 Bayer Intellectual Property Gmbh 6 substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
MY166889A (en) 2011-08-24 2018-07-24 Millennium Pharm Inc Inhibitors of nedd8-activating enzyme
JP2013237634A (ja) 2012-05-14 2013-11-28 Dainippon Sumitomo Pharma Co Ltd 縮環イミダゾロン誘導体
GB201302927D0 (en) 2013-02-20 2013-04-03 Cancer Therapeutics Crc Pty Ltd Compounds
TWI647227B (zh) 2013-02-28 2019-01-11 日商安斯泰來製藥股份有限公司 2-醯胺噻唑衍生物或其鹽
MX370140B (es) 2014-06-06 2019-12-03 Astellas Pharma Inc Derivado de 2-acilaminotiazol o sal del mismo.
JP6569678B2 (ja) 2014-08-26 2019-09-04 アステラス製薬株式会社 2−アミノチアゾール誘導体またはその塩
EP3290037A4 (en) 2015-04-28 2019-01-23 Astellas Pharma Inc. PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION
WO2018112840A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. 6, 5-fused heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor
WO2018157857A1 (zh) 2017-03-03 2018-09-07 江苏豪森药业集团有限公司 凋亡信号调节激酶抑制剂及其制备方法和应用
JP7291632B2 (ja) 2017-12-21 2023-06-15 杏林製薬株式会社 夜間頻尿治療剤
JPWO2019189766A1 (ja) 2018-03-30 2021-04-08 持田製薬株式会社 新規ビアリールアミド誘導体
TW202012415A (zh) 2018-05-08 2020-04-01 瑞典商阿斯特捷利康公司 化學化合物
MY202833A (en) 2018-05-08 2024-05-24 Nippon Shinyaku Co Ltd Azabenzimidazole compounds and pharmaceutical
CA3160838A1 (en) 2019-11-13 2021-05-20 Nippon Shinyaku Co., Ltd. Therapeutic agents and prophylactic agents for functional gastrointestinal disorders and xerostomia
CA3161582A1 (en) 2019-11-13 2021-05-20 Nippon Shinyaku Co., Ltd. Azabenzimidazole compound and medicine

Also Published As

Publication number Publication date
KR102819951B1 (ko) 2025-06-13
BR112020022662A2 (pt) 2021-02-09
MX2020011855A (es) 2021-01-20
MA52587B1 (fr) 2024-10-31
SA520420487B1 (ar) 2024-03-17
EP3792260B1 (en) 2024-09-11
KR20210006437A (ko) 2021-01-18
LT3792260T (lt) 2024-10-25
AU2019265134A1 (en) 2020-12-17
EP3792260A4 (en) 2022-02-09
DK3792260T3 (da) 2024-10-14
AU2019265134B2 (en) 2024-02-29
US12319683B2 (en) 2025-06-03
IL278517A (en) 2020-12-31
HUE068695T2 (hu) 2025-01-28
PH12020551873A1 (en) 2021-05-31
PL3792260T3 (pl) 2024-12-02
US20210371412A1 (en) 2021-12-02
IL278517B1 (en) 2024-05-01
IL278517B2 (en) 2024-09-01
ES2992256T3 (es) 2024-12-11
PT3792260T (pt) 2024-10-02
TWI868068B (zh) 2025-01-01
WO2019216294A1 (ja) 2019-11-14
EP3792260A1 (en) 2021-03-17
CN112368282A (zh) 2021-02-12
SMT202400407T1 (it) 2024-11-15
JPWO2019216294A1 (ja) 2021-05-13
MD3792260T2 (ro) 2024-12-31
CL2020002868A1 (es) 2021-04-16
CO2020013848A2 (es) 2021-01-29
CA3099655A1 (en) 2019-11-14
TW202016108A (zh) 2020-05-01
MA52587A (fr) 2021-03-17
ECSP20078586A (es) 2021-01-29
CN112368282B (zh) 2023-10-13
UA126774C2 (uk) 2023-02-01
JP7235047B2 (ja) 2023-03-08
HRP20241414T1 (hr) 2024-12-20
FI3792260T3 (fi) 2024-10-01
ZA202007164B (en) 2024-06-26
PE20211384A1 (es) 2021-07-27
SG11202011003TA (en) 2020-12-30
MY202833A (en) 2024-05-24
SI3792260T1 (sl) 2024-11-29

Similar Documents

Publication Publication Date Title
JP7235047B2 (ja) アザベンゾイミダゾール化合物及び医薬
US8822448B2 (en) Pyrazoloquinoline compound
KR20190033607A (ko) Malt1 저해제로서의 치환 티아졸로-피리딘 화합물
KR20100092443A (ko) 치환된 n-페닐-피롤리디닐메틸피롤리딘 아미드 및 히스타민 h3 수용체 조절제로서의 이의 치료적 용도
JP7627661B2 (ja) アザベンゾイミダゾール化合物及び医薬
AU2020382209A1 (en) Therapeutic agent and prophylactic agent for functional gastrointestinal disorders and xerostomia
RU2804485C2 (ru) Азабензимидазольные соединения и фармкомпозиция
CN118369323A (zh) 作为shp2抑制剂的杂环化合物、包括该杂环化合物的组合物、及其使用方法
HK40046611B (en) Azabenzimidazole compounds and pharmaceutical
HK40046611A (en) Azabenzimidazole compounds and pharmaceutical
HK40075503A (en) Azabenzimidazole compound and medicine
HK40045733B (en) Azabenzimidazole compounds and pharmaceutical
HK40045733A (en) Azabenzimidazole compounds and pharmaceutical
HK40076325A (en) Azabenzimidazole compound and medicine
CA3008653A1 (en) Bruton's tyrosine kinase inhibitors
OA18099A (en) 2-Amino-6-Methyl-4,4a,5,6-Tetrahydropyrano[3,4-d][1,3]Thiazin-8a(8H)-YL-1,3Thiazol4-YL Amides